Related Experiment Video
Updated: Apr 22, 2026

09:24
3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
Published on: September 13, 2018
8.4K
KLF8 is required for bladder cancer cell proliferation and migration
Kai Liang1, Tao Liu2, Ning Chu1
1Department of Urology, Hospital of Heilongjiang Province, Harbin, People's Republic of China.
Biotechnology and Applied Biochemistry
|October 18, 2014
Summary
Krüppel-like factor 8 (KLF8) promotes bladder cancer cell growth and migration. Inhibiting KLF8 with siRNA significantly reduced proliferation and metastasis, suggesting KLF8 as a therapeutic target for bladder cancer gene therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Krüppel-like factor 8 (KLF8) is a transcription factor implicated in epithelial-mesenchymal transition and cancer metastasis.
- While KLF8 overexpression is noted in various cancers, its specific role in human bladder cancer is uncharacterized.
Purpose of the Study:
- To investigate the functional role of KLF8 in bladder cancer cell proliferation and migration.
- To evaluate the potential of KLF8 inhibition as a therapeutic strategy for bladder cancer.
Main Methods:
- Lentivirus-mediated small interfering RNA (siRNA) was used to specifically downregulate KLF8 expression in T24 and BT5637 bladder cancer cell lines.
- Cell proliferation, colony formation, cell cycle, and migration assays were performed.
- Expression levels of key proteins involved in epithelial-mesenchymal transition (vimentin, N-cadherin, β-catenin) were analyzed.
Main Results:
- KLF8 knockdown significantly inhibited bladder cancer cell proliferation and colony formation.
- KLF8 knockdown led to cell cycle arrest at the G0/G1 phase in T24 cells.
- Cell migration was markedly reduced following KLF8 knockdown.
- KLF8 inhibition decreased vimentin and N-cadherin expression while increasing β-catenin expression.
Conclusions:
- KLF8 plays a critical role in regulating the proliferation and migration of bladder cancer cells.
- Targeting KLF8 with siRNA presents a promising avenue for bladder cancer gene therapy.

